Investigators showed that an US FDA-approved drug Eltrombopag bound to the basic helix-loop-helix-leucine zipper domain of transcription factor EB (TFEB), and disrupted TFEB-DNA interaction in vitro and in cellular context.
[Proceedings Of The National Academy Of Sciences Of The United States Of America]